The launch of opicapone for Parkinson's disease: negatives versus positives.
作者： Ana Castro Caldas , Tiago Teodoro , Joaquim J Ferreira
DOI: 10.1080/14740338.2018.1433659
关键词: Internal medicine 、 COMT inhibitor 、 Oncology 、 Clinical trial 、 Medicine 、 Tolerability 、 Safety profile 、 Parkinson's disease 、 Third generation 、 Adverse effect
摘要: ABSTRACTIntroduction: Opicapone is a novel, third generation COMT inhibitor approved for the treatment of Parkinson’s disease. Safety and tolerability data critical to determine benefit-harm balance anticipate therapeutic adherence.Areas covered: This review evaluates safety profile opicapone. These were extracted from all published clinical trials, including preclinical, phase I, II III studies as well postmarketing data. was safe tolerated, with frequencies treatment-emergent adverse events similar placebo.Expert opinion: have shown good profile. adds its proven efficacy convenient once-daily administration, supporting role opicapone first-line therapy motor complications in disease patients.
sci-hub.se 参考文章(15)
M J Bonifácio, L Torrão, A I Loureiro, P N Palma, L C Wright, P Soares-da-Silva, Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat. British Journal of Pharmacology. ,vol. 172, pp. 1739- 1752 ,(2015) , 10.1111/BPH.13020
Andrew J. Lees, Eduardo Tolosa, C. Warren Olanow, Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr. Movement Disorders. ,vol. 30, pp. 19- 36 ,(2015) , 10.1002/MDS.26120
D. J. Brooks, Safety and tolerability of COMT inhibitors. Neurology. ,vol. 62, ,(2004) , 10.1212/WNL.62.1_SUPPL_1.S39
M.J. Bonifácio, J.S. Sutcliffe, L. Torrão, L.C. Wright, P. Soares-da-Silva, Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor Neuropharmacology. ,vol. 77, pp. 334- 341 ,(2014) , 10.1016/J.NEUROPHARM.2013.10.014
L. Bet, S. R. Bareggi, F. Pacei, G. Bondiolotti, G. Meola, A. H. V Schapira, Bimodal administration of entacapone in Parkinson's disease patients improves motor control. European Journal of Neurology. ,vol. 15, pp. 268- 273 ,(2008) , 10.1111/J.1468-1331.2007.02043.X
Vincenzo Bonifati, Giuseppe Meco, None, New, Selective Catechol-O-Methyltransferase Inhibitors as Therapeutic Agents in Parkinson’s Disease Pharmacology & Therapeutics. ,vol. 81, pp. 1- 36 ,(1999) , 10.1016/S0163-7258(98)00032-1
László E. Kiss, Humberto S. Ferreira, Leonel Torrão, Maria João Bonifácio, P. Nuno Palma, Patrício Soares-da-Silva, David A. Learmonth, Discovery of a Long-Acting, Peripherally Selective Inhibitor of Catechol-O-methyltransferase Journal of Medicinal Chemistry. ,vol. 53, pp. 3396- 3411 ,(2010) , 10.1021/JM1001524
Roberto Pinto, Philippe l'Hostis, Alain Patat, Marie-Claude Homery, Amílcar Falcão, Teresa Nunes, José-Francisco Rocha, Patrício Soares-da-Silva, Evaluation of opicapone on cardiac repolarization in a thorough QT/QTc study Clinical pharmacology in drug development. ,vol. 4, pp. 454- 462 ,(2015) , 10.1002/CPDD.188
José-Francisco Rocha, Joaquim J. Ferreira, Amílcar Falcão, Ana Santos, Roberto Pinto, Teresa Nunes, Luis Almeida, Patrício Soares-da-Silva, Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease. Clinical pharmacology in drug development. ,vol. 5, pp. 232- 240 ,(2016) , 10.1002/CPDD.217
J. J. Ferreira, J.-F. Rocha, A. Falcão, A. Santos, R. Pinto, T. Nunes, P. Soares-da-Silva, Effect of opicapone on levodopa pharmacokinetics, catechol‐O‐methyltransferase activity and motor fluctuations in patients with Parkinson's disease European Journal of Neurology. ,vol. 22, pp. 815- ,(2015) , 10.1111/ENE.12666